India has long been known as the world's pharmacy. Today, it is positioning itself as a global hub for drug discovery, biologics, and AI-driven research.

The Opportunity Has Arrived

The numbers tell the story. According to IBEF, India's bioeconomy has grown from $10 billion in 2014 to $130 billion today, with projections of $300 billion by 2030. As reported by Business Today, Telangana alone is targeting $22 billion (₹2 lakh crore) in life sciences investment over the next five years. Conversations at BioAsia 2026, where over 4,000 delegates gathered under the theme "TechBio Unleashed," reinforced what the numbers already show. Genome Valley now hosts over 200 companies, world-class CDMOs and CROs, and deep talent pools. The ecosystem is maturing, and with it, demand for infrastructure that can support the next phase of growth.

What TechBio Demands

But TechBio does not fit neatly into traditional buildings. These companies need facilities that are part wet lab, part data centre, and part automation hub. AI-driven discovery requires serious computing power and cooling. Robotics and high-throughput screening demand flexible layouts, higher floor loads, and ceiling-mounted services. And these requirements evolve rapidly.

There is also the sustainability tension. TechBio is energy-intensive by nature, but tenants are the ones who face the real ESG pressure. With scope 3 emissions now including leased facilities, green credentials have become a procurement criterion, not a nice-to-have.

The Infrastructure Gap

Here's the challenge: life sciences companies require real estate that is purpose-built to strict specifications. Biotech firms need wet labs with specialised ventilation, filtration, and containment systems. Pharma companies require clean rooms and controlled research environments. TechBio sits at the intersection, requiring the environmental controls of a lab, the power density of a data centre, and the flexibility of a research campus.

The current lack of specialised real estate infrastructure in India poses challenges to this growth trajectory.

Why Genome Valley

This is where Genome Valley's density matters. It is not just 200 companies in proximity. It is shared infrastructure, integrated supply chains, and talent that moves fluidly between organisations. For global companies, this co-location makes tech transfers faster and operations more efficient.

Ecosystem density creates optionality. When your research pivots, you need partners who can scale with you. When you need specialised CDMOs or clinical trial infrastructure, proximity matters. Genome Valley delivers that.

How We Build for It

Neovantage has been part of this ecosystem from the start. We operate 1.4 million square feet across 12 buildings, with over 40 tenants and over 95% occupancy.

Our buildings support wet labs, dry labs, chemistry, biology, formulation, and agri-tech without structural modification. Centralised MEP shafts and overhead service highways enable plug-and-play expansion. Customisable utility drops through ceiling service panels allow for rapid tenant fit-out. We have pre-engineered for high-diversity loads: power with 100% backup, chilled water, compressed air, vacuum, and specialty gases.

Higher floor-to-floor heights and increased slab loading accommodate equipment variability. Mechanical systems include VAV controls and dynamic air change rates that adjust to occupancy and usage. Directional airflow and provisions for fume hoods, biosafety cabinets, and clean-process enclosures are built in, not retrofitted.

Our buildings include LEED Gold and Platinum certified facilities, reflecting a clear commitment to sustainability and operational efficiency.

What's Next

We are expanding with two under-construction projects. Phase 2 of Building 4500 adds 164,000 sq ft alongside the expansion of Building 3600 to add 80,000 sq ft. Both complete in Q4 2026. These facilities follow the same design philosophy: core infrastructure pre-built to accelerate tenant fit-out, with layouts that remain adaptable as research programmes evolve.

The companies betting on India's TechBio moment are already here. The question now is whether the infrastructure can keep pace with the ambition.

Genome Valley's advantage isn't just what exists today. It's the capacity to absorb what's coming next.

We're building for that future.

‍